Concentrations of telithromycin
Introduction
Telithromycin (HMR 3647) belongs to the family of ketolides representing a new class of 14-membered ring macrolides. 1 Ketolides are characterized by a keto function in position 3 of the erythronolide A ring, which replaces the cladinose moiety. Telithromycin is a C11-C12 carbamate ketolide. On the carbamate residue, imidazolyl and pyridinyl rings are linked by a butyl chain. Telithromycin inhibits protein synthesis, acting mainly on the 50S ribosomal subunit.
Telithromycin possesses a well-balanced activity against all the relevant pathogens associated with respiratory tract infections, including pneumococci resistant to penicillin and erythromycin, as well as Haemophilus influenzae and Moraxella catarrhalis, atypical bacteria (Mycoplasma pneumoniae) or intracellular bacteria (Chlamydia pneumoniae and Legionella pneumophila). 1 The aim of this study was to measure concentrations of telithromycin in bronchial mucosa (BM), epithelial lining fluid (ELF), alveolar macrophages (AM) and plasma following multiple once daily oral dosing of 800 mg for 5 days before bronchoscopy in patients.
Patients and methods

Patients
Twenty-seven patients (11 female and 16 male) undergoing elective fibre-optic bronchoscopy were enrolled. Subjects were recruited from a respiratory outpatient clinic. Patients were divided into three nominal time windows of 2, 12 and 24 h after the last dose. All of the patients were over 18 years of age and all females were post-menopausal. The study was approved by the hospital ethics committee and all subjects gave written informed consent. Patients were excluded from the study if they had active lung infection, were receiving another antibiotic, had any unstable medical condition, any significant renal or hepatic disease, a history of allergy to macrolide antibiotics or were receiving theophyllines.
All subjects were screened within 14 days before bronchoscopy; screening included a detailed medical history, physical examination and blood samples for haematological, biochemical analysis and pre-dose microbiological assay. Bronchoscopy and sample collection was as described previously. 2 Briefly, at bronchoscopy BM samples were taken and broncho-alveolar lavage (BAL) was performed. A standard BAL was performed using 200 mL of pre-warmed 0.9% saline divided into four aliquots of 50 mL. The aspirate from the first lavage was discarded to avoid contamination with proximal airway fluids and cells, the remaining aliquots were pooled for analysis.
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Microbiological assay
Assay plates (Mast Laboratories, Bootle, UK) containing a base layer of Antibiotic Medium No. 1 adjusted to pH 8 with NaOH, were overlaid with the same medium seeded with Bacillius subtilis ATCC 6633/NCTC 10400 spore suspension (spore suspension adjusted to 80% light transmission at 54 nm). Calibrators, internal controls and quality assurance samples were prepared from known potency standard telithromycin powder (Aventis Pharma, Romainville, France) in human serum (E&O Laboratories, Bonnybridge, UK), pH 8 phosphate buffer and 9% NaCl for the assay of plasma, AM and BM and ELF, respectively. Calibrator ranges in serum, pH 8 buffer and 9% NaCl were 0.05-0.8 mg/L, 0.03-0.04 mg/L and 0.05-0.8 mg/L, respectively. Six millimetre diameter wells were punched into the agar and samples (calibrators, internal controls, quality assurance samples and tests) were applied in triplicate in a random pattern. Plates were incubated at 32°C for 18-20 h and zones of inhibition were measured using an Image Analyser (Imaging Associates, Teme, UK) pre-programmed with Bennet's calculation to obtain a line of best fit. 3 The lower limit of quantification of the assay was 0.03 mg/L. The assay was validated externally by Aventis Pharma before commencement of the bronchial study (30 serum samples correlation of assigned concentration and assayed concentration r 2 ϭ 0.9894).
Calculation of telithromycin concentration in ELF, BM and AM
Concentrations of telithromycin in ELF, BM and AM were calculated as described previously. 2 Briefly, the concentration of antibiotic in each of the sites was calculated as follows:
Bronchial biopsies. Seven patients were withdrawn from the study, one who withdrew consent before taking the medication; one with moderate diarrhoea; one with a creatinine clearance of Ͻ50 mL/min; one for administrative reasons because a spillage of disinfectant in theatre prevented the collection of samples; one with a minor adverse event (vomited the last tablet); and three patients who did not take all of the prescribed tablets. Individual patient results for each of the nominal time windows and ratios of site to plasma concentration are shown in the Table. Mean concentrations 
Discussion
The findings of this study show that there was good penetration of telithromycin into respiratory tissues after administration of multiple oral doses of 800 mg to patients undergoing diagnostic fibre-optic bronchoscopy. The mean site to serum ratios at c. 2 h for telithromycin in BM were slightly lower than those for clarithromycin, 4 but similar to those for erythromycin. 5 In ELF, telithromycin ratios were similar to those for clarithromycin yet higher than those seen for erythromycin. In the first time window there was considerable inter-subject variation. A possible reason for this is that the drug had not equilibrated between the various compartments at this early time post dosing. The greatest difference in ratios was noted with AMs where ratios of 94.1 and 40.8 for clarithromycin and telithromycin, respectively, were observed. Concentrations of telithromycin in BM and ELF exceeded for 24 h the mean MIC 90 s of the common respiratory pathogens Streptococcus pneumoniae (0.12 mg/L) 1 
